Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KAINOS LaboratoriesTSE:4556 47 EV-to-EBIT is 9.99 as of Aug. 30, 2026, which is 99% above its 10-year median of 5.01. GuruFocus rates TSE:4556 with a GF Score™ of 47/100 and a GF Value™ of 円1,285.89. The stock has 6 warning signs investors should review. Among 477 Medical Devices & Instruments companies, KAINOS Laboratories ranks better than 78.62% on this metric.
The historical rank and industry rank for KAINOS Laboratories's EV-to-EBIT or its related term are showing as below:
TSE:4556'
s EV-to-EBIT Range Over the Past 10 Years
Min: 2.5 Med: 5.01 Max: 11.85
Current: 9.99
During the past 13 years, the highest EV-to-EBIT of KAINOS Laboratories was 11.85. The lowest was 2.50. And the median was 5.01.
TSE:4556's EV-to-EBIT is ranked better than 78.62% of 477
companies
in the Medical Devices & Instruments industry
Industry Median: 18.99
vs TSE:4556: 9.99
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
KAINOS Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was 円6,375 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. KAINOS Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円640 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAINOS Laboratories EV-to-EBIT Related Terms
KAINOS Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for KAINOS Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4556 vs ISRG, BDX, MDLN: EV-to-EBIT Comparison
For the Medical Instruments & Supplies subindustry, KAINOS Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KAINOS Laboratories EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KAINOS Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where KAINOS Laboratories's EV-to-EBIT falls into.
KAINOS Laboratories's current Enterprise Value is 円6,401 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. KAINOS Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was 円640 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KAINOS Laboratories (TSE:4556) has a EV-to-EBIT of 9.99 as of Aug. 30, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on KAINOS Laboratories and its competitors. This is 99% above median its historical median of 5.01. Over the past decade, KAINOS Laboratories' EV-to-EBIT has ranged from 2.50 to 11.85. According to the industry distribution chart, KAINOS Laboratories ranks #102 out of 477 companies in the Medical Devices & Instruments industry, placing it in the top 21.4%.
Is KAINOS Laboratories' EV-to-EBIT too high?
KAINOS Laboratories' current EV-to-EBIT of 9.99 is 99% above median its 10-year median of 5.01. Over the past 10 years, this metric has ranged from a low of 2.50 to a high of 11.85. The Medical Devices & Instruments industry median EV-to-EBIT is 18.99. KAINOS Laboratories' value of 9.99 is 47.4% below this industry median. Based on the distribution chart, KAINOS Laboratories ranks #102 out of 477 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, KAINOS Laboratories has a GF Score™ of 47/100, reflecting its overall financial health beyond just this single metric.
How does KAINOS Laboratories' EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, KAINOS Laboratories ranks #102 out of 477 companies for EV-to-EBIT. This places KAINOS Laboratories in the top 21% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 18.99. KAINOS Laboratories' value of 9.99 is 47.4% below this benchmark. Historically, KAINOS Laboratories' own EV-to-EBIT has ranged from 2.50 to 11.85 over the past decade. While the company's 10-year median is 5.01 vs. the industry median of 18.99, KAINOS Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 18.99, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KAINOS Laboratories's current EV-to-EBIT of 9.99 is 47.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on KAINOS Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 18.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KAINOS Laboratories's current EV-to-EBIT is 9.99, which is 99% above median its own 10-year median of 5.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KAINOS Laboratories stock overvalued right now?
KAINOS Laboratories (TSE:4556) has a current EV-to-EBIT of 9.99. The stock's GF Value™ is 円1,285.89, compared to a current price of 円2,268.00 — trading 76.4% above its estimated fair value. The current EV-to-EBIT is 9.99, which is 99% above median its 10-year median of 5.01 and 47.4% below the Medical Devices & Instruments industry median of 18.99. KAINOS Laboratories' overall GF Score™ is 47/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For KAINOS Laboratories (TSE:4556), the current EV-to-EBIT is 9.99 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KAINOS Laboratories (TSE:4556) Overvalued in 2026?
Based on GuruFocus' analysis, KAINOS Laboratories stock appears to be overvalued.
The current stock price of 円2,268.00 is trading 76.4% above its estimated GF Value™ of 円1,285.89.
Key valuation signals for TSE:4556:
EV-to-EBIT: 9.99 (99% above median its 10-year median of 5.01)
GF Value™: 円1,285.89 vs. price of 円2,268.00 (76.4% above fair value)
Industry Position: 47.4% below the Medical Devices & Instruments median (#102 of 477)
No single metric tells the full story. See the TSE:4556 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KAINOS Laboratories Inc is focused on the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products. It also manufactures, sells, and exports/imports physicochemical measuring equipment for medical use.
47GF Score
Get the complete analysis for TSE:4556
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4556 has been successfully added to your 
